A reduced CDKN2A copy number stands as a harbinger of adverse prognosis (16), while its mutation often coincides with a heightened TMB, another indicator of poor prognosis in HNSCC (25). This evidence concerns the gene CDKN2A and head and neck squamous cell carcinoma.